According to A Latest intelligence report published by Market IntelliX, the global market for Drugs for Vaginal Fungal Infections should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

China Drugs for Vaginal Fungal Infections market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

The United States Drugs for Vaginal Fungal Infections market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

In terms of type, Fluconazole segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Hospital has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.

The global key manufacturers of Drugs for Vaginal Fungal Infections include Pfizer Inc., Bausch Health Companies Inc, ANl Pharmaceuticals, Inc, Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals and PEPTONIC Medical AB, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive study of the global market for Drugs for Vaginal Fungal Infections. Report Highlights:

(1) Global Drugs for Vaginal Fungal Infections market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.

(2) Global Drugs for Vaginal Fungal Infections market competitive situation, revenue and market share, from 2018 to 2022.

(3) China Drugs for Vaginal Fungal Infections market competitive situation, revenue and market share, from 2018 to 2022.

(4) Global Drugs for Vaginal Fungal Infections segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Drugs for Vaginal Fungal Infections segment by type and by application and regional segment by type and by application.

(6) Drugs for Vaginal Fungal Infections industry supply chain, upstream, midstream and downstream analysis.

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by type, covers

Fluconazole

Nystatin

Flucytosine

Clotrimazole

Others

Market segment by application, can be divided into

Hospital

Clinic

Others

Market segment by players, this report covers

Pfizer Inc.

Bausch Health Companies Inc

ANl Pharmaceuticals, Inc

Hikma Pharmaceuticals Plc

Lupin Limited

Mycovia Pharmaceuticals, Inc.

Glenmark Pharmaceuticals Limited

Unique Pharmaceuticals

PEPTONIC Medical AB

Aurobindo Pharma Limited

Dr. Reddy's Laboratories

SCYNEXIS,Inc.

Basilea Pharmaceutica Ltd.

Astellas Pharma lnc.

Grupo Ferrer Internacional,S.A.

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc.

Cidara Therapeutics, Inc.

Amplyx Pharmaceuticals Inc.

1 Market Overview

1.1 Product Overview and Scope of Drugs for Vaginal Fungal Infections

1.2 Global Drugs for Vaginal Fungal Infections Market Size and Forecast

1.3 China Drugs for Vaginal Fungal Infections Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Drugs for Vaginal Fungal Infections Share in Global Market, 2018-2029

1.4.2 Drugs for Vaginal Fungal Infections Market Size: China VS Global, 2018-2029

1.5 Drugs for Vaginal Fungal Infections Market Dynamics

1.5.1 Drugs for Vaginal Fungal Infections Market Drivers

1.5.2 Drugs for Vaginal Fungal Infections Market Restraints

1.5.3 Drugs for Vaginal Fungal Infections Industry Trends

1.5.4 Drugs for Vaginal Fungal Infections Industry Policy

2 Global Competitive Situation by Company

2.1 Global Drugs for Vaginal Fungal Infections Revenue by Company (2018-2023)

2.2 Global Drugs for Vaginal Fungal Infections Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Drugs for Vaginal Fungal Infections Concentration Ratio

2.4 Global Drugs for Vaginal Fungal Infections Mergers & Acquisitions, Expansion Plans

2.5 Global Drugs for Vaginal Fungal Infections Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Drugs for Vaginal Fungal Infections Revenue by Company (2018-2023)

3.2 China Drugs for Vaginal Fungal Infections Drugs for Vaginal Fungal Infections Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Drugs for Vaginal Fungal Infections, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)

4 Industry Chain Analysis

4.1 Drugs for Vaginal Fungal Infections Industry Chain

4.2 Drugs for Vaginal Fungal Infections Upstream Analysis

4.3 Drugs for Vaginal Fungal Infections Midstream Analysis

4.4 Drugs for Vaginal Fungal Infections Downstream Analysis

5 Sights by Type

5.1 Drugs for Vaginal Fungal Infections Classification

5.1.1 Fluconazole

5.1.2 Nystatin

5.1.3 Flucytosine

5.1.4 Clotrimazole

5.1.5 Others

5.2 By Type, Global Drugs for Vaginal Fungal Infections Market Size & CAGR, 2018 VS 2022 VS 2029

5.3 By Type, Global Drugs for Vaginal Fungal Infections Revenue, 2018-2029

6 Sights by Application

6.1 Drugs for Vaginal Fungal Infections Segment by Application

6.1.1 Hospital

6.1.2 Clinic

6.1.3 Others

6.2 By Application, Global Drugs for Vaginal Fungal Infections Market Size & CAGR, 2018 VS 2022 VS 2029

6.3 By Application, Global Drugs for Vaginal Fungal Infections Revenue, 2018-2029

7 Sales Sights by Region

7.1 By Region, Global Drugs for Vaginal Fungal Infections Market Size, 2018 VS 2022 VS 2029

7.2 By Region, Global Drugs for Vaginal Fungal Infections Market Size, 2018-2029

7.3 North America

7.3.1 North America Drugs for Vaginal Fungal Infections Market Size & Forecasts, 2018-2029

7.3.2 By Country, North America Drugs for Vaginal Fungal Infections Market Size Market Share

7.4 Europe

7.4.1 Europe Drugs for Vaginal Fungal Infections Market Size & Forecasts, 2018-2029

7.4.2 By Country, Europe Drugs for Vaginal Fungal Infections Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Drugs for Vaginal Fungal Infections Market Size & Forecasts, 2018-2029

7.5.2 By Country/Region, Asia Pacific Drugs for Vaginal Fungal Infections Market Size Market Share

7.6 South America

7.6.1 South America Drugs for Vaginal Fungal Infections Market Size & Forecasts, 2018-2029

7.6.2 By Country, South America Drugs for Vaginal Fungal Infections Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Drugs for Vaginal Fungal Infections Market Size & CAGR，2018 VS 2022 VS 2029

8.2 By Country, Global Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.3 U.S.

8.3.1 U.S. Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.3.2 By Company, U.S. Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.3.3 By Type, U.S. Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.3.4 By Application, U.S. Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.4.2 By Company, Europe Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.4.3 By Type, Europe Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.4.4 By Application, Europe Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.5 China

8.5.1 China Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.5.2 By Company, China Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.5.3 By Type, China Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.5.4 By Application, China Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.6.2 By Company, Japan Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.6.3 By Type, Japan Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.6.4 By Application, Japan Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.7.2 By Company, South Korea Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.7.3 By Type, South Korea Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.7.4 By Application, South Korea Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.8.2 By Company, Southeast Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.8.3 By Type, Southeast Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.8.4 By Application, Southeast Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.9 India

8.9.1 India Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.9.2 By Company, India Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.9.3 By Type, India Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.9.4 By Application, India Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.10 Middle East & Asia

8.10.1 Middle East & Asia Drugs for Vaginal Fungal Infections Market Size, 2018-2029

8.10.2 By Company, Middle East & Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

8.10.3 By Type, Middle East & Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

8.10.4 By Application, Middle East & Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

9 Global Manufacturers Profile

9.1 Pfizer Inc.

9.1.1 Pfizer Inc. Company Information, Head Office, Market Area and Industry Position

9.1.2 Pfizer Inc. Company Profile and Main Business

9.1.3 Pfizer Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.1.4 Pfizer Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.1.5 Pfizer Inc. Recent Developments

9.2 Bausch Health Companies Inc

9.2.1 Bausch Health Companies Inc Company Information, Head Office, Market Area and Industry Position

9.2.2 Bausch Health Companies Inc Company Profile and Main Business

9.2.3 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.2.4 Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.2.5 Bausch Health Companies Inc Recent Developments

9.3 ANl Pharmaceuticals, Inc

9.3.1 ANl Pharmaceuticals, Inc Company Information, Head Office, Market Area and Industry Position

9.3.2 ANl Pharmaceuticals, Inc Company Profile and Main Business

9.3.3 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.3.4 ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.3.5 ANl Pharmaceuticals, Inc Recent Developments

9.4 Hikma Pharmaceuticals Plc

9.4.1 Hikma Pharmaceuticals Plc Company Information, Head Office, Market Area and Industry Position

9.4.2 Hikma Pharmaceuticals Plc Company Profile and Main Business

9.4.3 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.4.4 Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.4.5 Hikma Pharmaceuticals Plc Recent Developments

9.5 Lupin Limited

9.5.1 Lupin Limited Company Information, Head Office, Market Area and Industry Position

9.5.2 Lupin Limited Company Profile and Main Business

9.5.3 Lupin Limited Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.5.4 Lupin Limited Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.5.5 Lupin Limited Recent Developments

9.6 Mycovia Pharmaceuticals, Inc.

9.6.1 Mycovia Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position

9.6.2 Mycovia Pharmaceuticals, Inc. Company Profile and Main Business

9.6.3 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.6.4 Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.6.5 Mycovia Pharmaceuticals, Inc. Recent Developments

9.7 Glenmark Pharmaceuticals Limited

9.7.1 Glenmark Pharmaceuticals Limited Company Information, Head Office, Market Area and Industry Position

9.7.2 Glenmark Pharmaceuticals Limited Company Profile and Main Business

9.7.3 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.7.4 Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.7.5 Glenmark Pharmaceuticals Limited Recent Developments

9.8 Unique Pharmaceuticals

9.8.1 Unique Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

9.8.2 Unique Pharmaceuticals Company Profile and Main Business

9.8.3 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.8.4 Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.8.5 Unique Pharmaceuticals Recent Developments

9.9 PEPTONIC Medical AB

9.9.1 PEPTONIC Medical AB Company Information, Head Office, Market Area and Industry Position

9.9.2 PEPTONIC Medical AB Company Profile and Main Business

9.9.3 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.9.4 PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.9.5 PEPTONIC Medical AB Recent Developments

9.10 Aurobindo Pharma Limited

9.10.1 Aurobindo Pharma Limited Company Information, Head Office, Market Area and Industry Position

9.10.2 Aurobindo Pharma Limited Company Profile and Main Business

9.10.3 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.10.4 Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.10.5 Aurobindo Pharma Limited Recent Developments

9.11 Dr. Reddy's Laboratories

9.11.1 Dr. Reddy's Laboratories Company Information, Head Office, Market Area and Industry Position

9.11.2 Dr. Reddy's Laboratories Company Profile and Main Business

9.11.3 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.11.4 Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.11.5 Dr. Reddy's Laboratories Recent Developments

9.12 SCYNEXIS,Inc.

9.12.1 SCYNEXIS,Inc. Company Information, Head Office, Market Area and Industry Position

9.12.2 SCYNEXIS,Inc. Company Profile and Main Business

9.12.3 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.12.4 SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.12.5 SCYNEXIS,Inc. Recent Developments

9.13 Basilea Pharmaceutica Ltd.

9.13.1 Basilea Pharmaceutica Ltd. Company Information, Head Office, Market Area and Industry Position

9.13.2 Basilea Pharmaceutica Ltd. Company Profile and Main Business

9.13.3 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.13.4 Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.13.5 Basilea Pharmaceutica Ltd. Recent Developments

9.14 Astellas Pharma lnc.

9.14.1 Astellas Pharma lnc. Company Information, Head Office, Market Area and Industry Position

9.14.2 Astellas Pharma lnc. Company Profile and Main Business

9.14.3 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.14.4 Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.14.5 Astellas Pharma lnc. Recent Developments

9.15 Grupo Ferrer Internacional,S.A.

9.15.1 Grupo Ferrer Internacional,S.A. Company Information, Head Office, Market Area and Industry Position

9.15.2 Grupo Ferrer Internacional,S.A. Company Profile and Main Business

9.15.3 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.15.4 Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.15.5 Grupo Ferrer Internacional,S.A. Recent Developments

9.16 Pacgen Life Science Corporation

9.16.1 Pacgen Life Science Corporation Company Information, Head Office, Market Area and Industry Position

9.16.2 Pacgen Life Science Corporation Company Profile and Main Business

9.16.3 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.16.4 Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.16.5 Pacgen Life Science Corporation Recent Developments

9.17 NovaDigm Therapeutics, Inc.

9.17.1 NovaDigm Therapeutics, Inc. Company Information, Head Office, Market Area and Industry Position

9.17.2 NovaDigm Therapeutics, Inc. Company Profile and Main Business

9.17.3 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.17.4 NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.17.5 NovaDigm Therapeutics, Inc. Recent Developments

9.18 Cidara Therapeutics, Inc.

9.18.1 Cidara Therapeutics, Inc. Company Information, Head Office, Market Area and Industry Position

9.18.2 Cidara Therapeutics, Inc. Company Profile and Main Business

9.18.3 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.18.4 Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.18.5 Cidara Therapeutics, Inc. Recent Developments

9.19 Amplyx Pharmaceuticals Inc.

9.19.1 Amplyx Pharmaceuticals Inc. Company Information, Head Office, Market Area and Industry Position

9.19.2 Amplyx Pharmaceuticals Inc. Company Profile and Main Business

9.19.3 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

9.19.4 Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

9.19.5 Amplyx Pharmaceuticals Inc. Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Table 1. Drugs for Vaginal Fungal Infections Market Size & CAGR: China VS Global, (US$ Million), 2018-2029

Table 2. Drugs for Vaginal Fungal Infections Market Restraints

Table 3. Drugs for Vaginal Fungal Infections Market Trends

Table 4. Drugs for Vaginal Fungal Infections Industry Policy

Table 5. Global Drugs for Vaginal Fungal Infections Revenue by Company (2018-2023) & (US$ million)

Table 6. Global Drugs for Vaginal Fungal Infections Revenue Market Share by Company (2018-2023)

Table 7. Global Drugs for Vaginal Fungal Infections Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Drugs for Vaginal Fungal Infections Mergers & Acquisitions, Expansion Plans

Table 9. Global Drugs for Vaginal Fungal Infections Manufacturers Product Type

Table 10. China Drugs for Vaginal Fungal Infections Revenue by Company (2018-2023) & (US$ million)

Table 11. China Drugs for Vaginal Fungal Infections Revenue Market Share by Company (2018-2023)

Table 12. Global Key Players of Drugs for Vaginal Fungal Infections Upstream (Raw Materials)

Table 13. Global Drugs for Vaginal Fungal Infections Typical Customers

Table 14. Drugs for Vaginal Fungal Infections Typical Distributors

Table 15. By Type, Global Drugs for Vaginal Fungal Infections Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 16. By Application, Global Drugs for Vaginal Fungal Infections Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 17. By Region, Global Drugs for Vaginal Fungal Infections Market Size, 2018 VS 2022 VS 2029, US$ Million

Table 18. By Region, Global Drugs for Vaginal Fungal Infections Revenue, 2018-2029, US$ Million

Table 19. By Country, Global Drugs for Vaginal Fungal Infections Revenue & CAGR，2018 VS 2022 VS 2029, US$ Million

Table 20. By Country, Global Drugs for Vaginal Fungal Infections Revenue, 2018-2029, US$ Million

Table 21. By Country, Global Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2029

Table 22. Pfizer Inc. Company Information, Head Office, Market Area and Industry Position

Table 23. Pfizer Inc. Company Profile and Main Business

Table 24. Pfizer Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 25. Pfizer Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 26. Pfizer Inc. Recent Developments

Table 27. Bausch Health Companies Inc Company Information, Head Office, Market Area and Industry Position

Table 28. Bausch Health Companies Inc Company Profile and Main Business

Table 29. Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 30. Bausch Health Companies Inc Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 31. Bausch Health Companies Inc Recent Developments

Table 32. ANl Pharmaceuticals, Inc Company Information, Head Office, Market Area and Industry Position

Table 33. ANl Pharmaceuticals, Inc Company Profile and Main Business

Table 34. ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 35. ANl Pharmaceuticals, Inc Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 36. ANl Pharmaceuticals, Inc Recent Developments

Table 37. Hikma Pharmaceuticals Plc Company Information, Head Office, Market Area and Industry Position

Table 38. Hikma Pharmaceuticals Plc Company Profile and Main Business

Table 39. Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 40. Hikma Pharmaceuticals Plc Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 41. Hikma Pharmaceuticals Plc Recent Developments

Table 42. Lupin Limited Company Information, Head Office, Market Area and Industry Position

Table 43. Lupin Limited Company Profile and Main Business

Table 44. Lupin Limited Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 45. Lupin Limited Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 46. Lupin Limited Recent Developments

Table 47. Mycovia Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position

Table 48. Mycovia Pharmaceuticals, Inc. Company Profile and Main Business

Table 49. Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 50. Mycovia Pharmaceuticals, Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 51. Mycovia Pharmaceuticals, Inc. Recent Developments

Table 52. Glenmark Pharmaceuticals Limited Company Information, Head Office, Market Area and Industry Position

Table 53. Glenmark Pharmaceuticals Limited Company Profile and Main Business

Table 54. Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 55. Glenmark Pharmaceuticals Limited Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 56. Glenmark Pharmaceuticals Limited Recent Developments

Table 57. Unique Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

Table 58. Unique Pharmaceuticals Company Profile and Main Business

Table 59. Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 60. Unique Pharmaceuticals Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 61. Unique Pharmaceuticals Recent Developments

Table 62. PEPTONIC Medical AB Company Information, Head Office, Market Area and Industry Position

Table 63. PEPTONIC Medical AB Company Profile and Main Business

Table 64. PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 65. PEPTONIC Medical AB Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 66. PEPTONIC Medical AB Recent Developments

Table 67. Aurobindo Pharma Limited Company Information, Head Office, Market Area and Industry Position

Table 68. Aurobindo Pharma Limited Company Profile and Main Business

Table 69. Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 70. Aurobindo Pharma Limited Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 71. Aurobindo Pharma Limited Recent Developments

Table 72. Dr. Reddy's Laboratories Company Information, Head Office, Market Area and Industry Position

Table 73. Dr. Reddy's Laboratories Company Profile and Main Business

Table 74. Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 75. Dr. Reddy's Laboratories Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 76. Dr. Reddy's Laboratories Recent Developments

Table 77. SCYNEXIS,Inc. Company Information, Head Office, Market Area and Industry Position

Table 78. SCYNEXIS,Inc. Company Profile and Main Business

Table 79. SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 80. SCYNEXIS,Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 81. SCYNEXIS,Inc. Recent Developments

Table 82. Basilea Pharmaceutica Ltd. Company Information, Head Office, Market Area and Industry Position

Table 83. Basilea Pharmaceutica Ltd. Company Profile and Main Business

Table 84. Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 85. Basilea Pharmaceutica Ltd. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 86. Basilea Pharmaceutica Ltd. Recent Developments

Table 87. Astellas Pharma lnc. Company Information, Head Office, Market Area and Industry Position

Table 88. Astellas Pharma lnc. Company Profile and Main Business

Table 89. Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 90. Astellas Pharma lnc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 91. Astellas Pharma lnc. Recent Developments

Table 92. Grupo Ferrer Internacional,S.A. Company Information, Head Office, Market Area and Industry Position

Table 93. Grupo Ferrer Internacional,S.A. Company Profile and Main Business

Table 94. Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 95. Grupo Ferrer Internacional,S.A. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 96. Grupo Ferrer Internacional,S.A. Recent Developments

Table 97. Pacgen Life Science Corporation Company Information, Head Office, Market Area and Industry Position

Table 98. Pacgen Life Science Corporation Company Profile and Main Business

Table 99. Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 100. Pacgen Life Science Corporation Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 101. Pacgen Life Science Corporation Recent Developments

Table 102. NovaDigm Therapeutics, Inc. Company Information, Head Office, Market Area and Industry Position

Table 103. NovaDigm Therapeutics, Inc. Company Profile and Main Business

Table 104. NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 105. NovaDigm Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 106. NovaDigm Therapeutics, Inc. Recent Developments

Table 107. Cidara Therapeutics, Inc. Company Information, Head Office, Market Area and Industry Position

Table 108. Cidara Therapeutics, Inc. Company Profile and Main Business

Table 109. Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 110. Cidara Therapeutics, Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 111. Cidara Therapeutics, Inc. Recent Developments

Table 112. Amplyx Pharmaceuticals Inc. Company Information, Head Office, Market Area and Industry Position

Table 113. Amplyx Pharmaceuticals Inc. Company Profile and Main Business

Table 114. Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Models, Specifications and Application

Table 115. Amplyx Pharmaceuticals Inc. Drugs for Vaginal Fungal Infections Revenue and Gross Margin, 2018-2023

Table 116. Amplyx Pharmaceuticals Inc. Recent Developments

List of Figure

Figure 1. Drugs for Vaginal Fungal Infections Picture

Figure 2. Global Drugs for Vaginal Fungal Infections Industry Market Size and Forecast (US$ million) & (2018-2029)

Figure 3. China Drugs for Vaginal Fungal Infections Revenue and Forecast (US$ million) & (2018-2029)

Figure 4. 2018-2029 China Drugs for Vaginal Fungal Infections Market Share of Global

Figure 5. Global Drugs for Vaginal Fungal Infections Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 6. Global Drugs for Vaginal Fungal Infections Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2018-2023

Figure 7. China Drugs for Vaginal Fungal Infections Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 8. China Drugs for Vaginal Fungal Infections Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2018-2023

Figure 9. Drugs for Vaginal Fungal Infections Industry Chain

Figure 10. Fluconazole

Figure 11. Nystatin

Figure 12. Flucytosine

Figure 13. Clotrimazole

Figure 14. Others

Figure 15. By Type, Global Drugs for Vaginal Fungal Infections Revenue, 2018-2029, US$ Million

Figure 16. By Type, Global Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2029

Figure 17. Hospital

Figure 18. Clinic

Figure 19. Others

Figure 20. By Application, Global Drugs for Vaginal Fungal Infections Revenue, 2018-2029, US$ Million

Figure 21. By Application, Global Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2029

Figure 22. By Region, Global Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2029

Figure 23. North America Drugs for Vaginal Fungal Infections Revenue & Forecasts, 2018-2029, US$ Million

Figure 24. By Country, North America Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

Figure 25. Europe Drugs for Vaginal Fungal Infections Revenue & Forecasts, 2018-2029, US$ Million

Figure 26. By Country, Europe Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

Figure 27. Asia Pacific Drugs for Vaginal Fungal Infections Revenue & Forecasts, 2018-2029, US$ Million

Figure 28. By Country/Region, Asia Pacific Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

Figure 29. South America Drugs for Vaginal Fungal Infections Revenue & Forecasts, 2018-2029, US$ Million

Figure 30. By Country, South America Drugs for Vaginal Fungal Infections Revenue Market Share, 2018-2023

Figure 31. Middle East & Africa Drugs for Vaginal Fungal Infections Revenue & Forecasts, 2018-2029, US$ Million

Figure 32. U.S. Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 33. By Company, U.S. Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 34. By Type, U.S. Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 35. By Application, U.S. Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 36. Europe Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 37. By Company, Europe Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 38. By Type, Europe Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 39. By Application, Europe Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 40. China Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 41. By Company, China Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 42. By Type, China Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 43. By Application, China Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 44. Japan Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 45. By Company, Japan Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 46. By Type, Japan Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 47. By Application, Japan Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 48. South Korea Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 49. By Company, South Korea Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 50. By Type, South Korea Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 51. By Application, South Korea Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 52. Southeast Asia Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 53. By Company, Southeast Asia Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 54. By Type, Southeast Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 55. By Application, Southeast Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 56. India Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 57. By Company, India Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 58. By Type, India Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 59. By Application, India Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 60. Middle East & Asia Drugs for Vaginal Fungal Infections Revenue, 2018-2029, (US$ Million)

Figure 61. By Company, Middle East & Asia Drugs for Vaginal Fungal Infections Market Share, 2018-2023

Figure 62. By Type, Middle East & Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 63. By Application, Middle East & Asia Drugs for Vaginal Fungal Infections Revenue Market Share, 2022 VS 2029

Figure 64. Research Methodology

Figure 65. Breakdown of Primary Interviews

Figure 66. Bottom-up Approaches

Figure 67. Top-down Approaches

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)